BioSpace News Archive

Madrigal Pharmaceuticals, Inc. today provides a summary of corporate updates and reports fourth quarter and full year 2022 financial results.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to inform shareholders that development of the BeaMed StingRay Laser System (the “StingRay System”) is progressing smoothly and ahead of estimated schedule.

PharmAla Biotech is pleased to announce the publication of a key Patent Cooperation Treaty application containing 6 Novel Chemical Entities.

Ardelyx, Inc. today announced it will hold a conference call on Thursday, March 2, 2023, at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2022 financial results and provide a business update.

Pasithea Therapeutics Corp. today announced that Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will deliver the Dr. Kenneth P. Johnson lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) on February 23 in San Diego, California.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three months and full year ended December 31, 2022.

Heska Corporation, a leading global provider of advanced veterinary diagnostic and specialty solutions, announced that members of Heska’s management team will present at three institutional investor conferences in March 2023.

Fore Biotherapeutics today announced that the first patient has been dosed in the global Phase 2 FORTE clinical trial evaluating FORE8394.

VBI Vaccines Inc. today announced that Jeff Baxter, VBI’s President and CEO, and David E. Anderson, VBI’s Chief Scientific Officer, will discuss the company’s hepatitis B (HBV) portfolio with covering analyst, Steven Seedhouse, Ph.D., from Raymond James & Associates, Inc.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company’s board of directors.